Naptumomab estafenatox targets the 5T4 tumor antigen, a 72-kDa oncofetal trophoblast protein expressed on many carcinomas, including renal cell carcinoma. This evidence concerns the gene TPBG and hereditary clear cell renal cell carcinoma.